Meloxicam for Postoperative Pain in Mohs Micrographic Surgery

What this Trial Is About

This research aims to explore alternative methods for managing postoperative pain in patients undergoing Mohs micrographic surgery, a precise technique for removing certain skin cancers. The study focuses on comparing different pain control options to improve comfort and overall well-being after surgery. Researchers hope to provide better information to the Mohs surgery community and offer patients a potential new choice of pain medication with fewer side effects than standard options. Participants will be randomly assigned to one of three groups: one group will receive a single dose of Meloxicam 7.5 mg followed by acetaminophen 500 mg as needed, another group will receive a single dose of Meloxicam 15 mg followed by acetaminophen 500 mg as needed, and the control group will take a single dose of acetaminophen 500 mg followed by alternating ibuprofen 200 mg and acetaminophen 500 mg every three hours, which is the current standard of care. Meloxicam will be given orally right after the surgical wound closure. During the study, participants will complete surveys about their pain levels and satisfaction with pain control. Researchers will monitor pain from enrollment until suture removal or wound check, typically between 7 to 21 days post-surgery. The study will evaluate how well Meloxicam controls pain compared to the standard pain medications. Safety and patient experience will be carefully observed throughout the trial period, which runs until August 2026.

Meloxicam in Mohs Micrographic Surgery